Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Paclitaxel

Paclitaxel stabilizes microtubules and interferes with their dynamics during cell division. Paclitaxel-treated cells exhibit defects in mitotic spindle assembly, chromosome segregation, and cell division. This blocks the progression of mitosis, and prolonged activation of the mitotic checkpoint triggers apoptosis. Paclitaxel is approved for the treatment of ovarian, breast and lung cancers and Kaposi's sarcoma.

catalogue number: P061
synonyms: Taxol
CAS: 33069-62-4
MW: 853.91 g/mol

References
Pharmacol Ther. 1984;25(1):83-125. PMID: 6149569
Med Res Rev. 1998 Sep;18(5):315-31. PMID: 9735872

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Pazopanib

Pazopanib is a potent inhibitor of all three VEGFR receptors, with IC50 values of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. It also displays significant activity against closely related kinases (notably, PDGFRb, c-Kit, FGF-R1, c-fms) with IC50 values in the submicromolar range. Pazopanib inhibits tumor vacsularization (angiogenesis) and thus blocks tumor growth.

catalogue number: P062
synonyms: GW786034, Armala, Votrient
CAS: 444731-52-6
MW: 473.98 g/mol

References
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83. PMID: 17164332
J Med Chem. 2008 Aug 14;51(15):4632-40. PMID: 18620382
Drugs. 2011 Mar 5;71(4):443-54. PMID: 21395357

Prices
  • 5 mg - 139 EUR
  • 25 mg - 556 EUR
  • 100 mg - 1668 EUR

PD-0332991

PD0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (CDK4, IC50=11 nmol/L) and CDK6 (IC50=16 nmol/L) that is inactive against other CDKs. It is a potent antiproliferative agent against retinoblastoma (Rb)-positive tumor cells in vitro, inducing G1 arrest with a concomitant reduction in the extent of phosphorylation of the pRb protein at Ser780 and Ser795.

catalogue number: P063
synonyms: palbociclib
CAS: 827022-32-2
MW: 483.99 g/mol (hydrochloride)

References
Mol Cancer Ther. 2004 Nov;3(11):1427-38. PMID: 15542782
J Med Chem. 2005 Apr 7;48(7):2388-406. PMID: 15801831
J Med Chem. 2006 Jun 29;49(13):3826-31. PMID: 16789739

Prices
  • 5 mg - 176 EUR
  • 25 mg - 704 EUR
  • 100 mg - 2112 EUR

Pelitinib

Pelitinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase in clinical trials. It inhibits EGF-induced phosphorylation of EGF-R and the growth of tumors that overexpress EGF-R in animal models.

catalogue number: P103
synonyms: EKB-569
CAS: 257933-82-7
MW: 467.92 g/mol

References
Bioorg Med Chem Lett. 2002 Oct 21;12(20):2893-7. PMID: 12270171
J Med Chem. 2003 Jan 2;46(1):49-63. PMID: 12502359
Mol Cancer Ther. 2004 Jan;3(1):21-7. PMID: 14749472

Prices
  • 5 mg - 148 EUR
  • 25 mg - 592 EUR
  • 100 mg - 1776 EUR

Perifosine

Perifosine is an oral Akt (protein kinase B, PKB) inhibitor that is currently being tested in clinical trials. Unlike most kinase inhibitors, which target the adenosine triphosphate-binding region, perifosine targets the pleckstrin homology domain of Akt, thereby preventing its translocation to the plasma membrane. Perifosine exerts both Akt-dependent and Akt-independent effects.

catalogue number: P064
synonyms: KRX-0401, NSC 639966161, D-21266
CAS: 157716-52-4
MW: 461.66 g/mol

References
Eur J Cancer. 1997 Mar;33(3):442-6. PMID: 9155530
Mol Cancer Ther. 2003 Nov;2(11):1093-103. PMID: 14617782

Prices
  • 5 mg - 194 EUR
  • 25 mg - 776 EUR
  • 100 mg - 2328 EUR

PHA-680632

PHA-680632 is a highly selective Aurora kinase inhibitor and an anticancer drug candidate. Its IC50 values against Aurora kinases A, B and C are 27, 135 and 120 nM, respectively, and it potently inhibits Histone H3 phosphorylation at Ser10. PHA-680632 is active against a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models.

catalogue number: P065
synonyms:
CAS: 398493-79-3
MW: 501.62 g/mol

References
Clin Cancer Res. 2006 Jul 1;12(13):4080-9. PMID: 16818708

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Pictilisib

Pictilisib, formerly known as GDC-0941, is a potent, selective, orally bioavailable inhibitor of PI3K. It inhibits PI3K isoform p110alpha with a single digit nanomolar IC50 value. The compound exhibits in vitro antiproliferative properties with submicromolar potency in PTEN-negative cells and clear PI3K pathway modulation. It is currently being evaluated in human clinical trials for the treatment of cancer.

catalogue number: P139
synonyms: GDC-0941
CAS: 957054-30-7
MW: 513.64 g/mol

References
J Med Chem. 2008 Sep 25;51(18):5522-32. PMID: 18754654
Mol Cancer Ther. 2009 Jul;8(7):1725-38. PMID: 19584227

Prices
  • 5 mg - 98 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR

Purvalanol A

Purvalanol A is cyclin-dependent kinase inhibitor with IC50 values of 4, 70, 850 and 75 nM for CDK1, CDK2, CDK4 and CDK5, respectively. It is a strong inducer of cell cycle arrest during the G2-M phase, and a potent suppressor of the anchorage-independent growth of c-Src-transformed cells. It also effectively suppressed the growth of human colon cancer HT29 and SW480 cells that express oncogenic Src.

catalogue number: P066
synonyms:
CAS: 212844-53-6
MW: 388.9 g/mol

References
Science. 1998 Jul 24;281(5376):533-8. PMID: 9677190
Int J Cancer. 2002 Feb 20;97(6):761-9. PMID: 11857351
Genes Cells. 2010 Oct;15(10):1051-62. PMID: 20825494